Trial ID or NCT#

NCT03270722

Status

NOT RECRUITING

Purpose

FLIP topography has been FDA cleared to evaluate a variety of esophageal conditions, but has never been evaluated in patients with scleroderma. The investigators hope to evaluate this technology in patients who have scleroderma and various esophageal symptoms, and compare to non-scleroderma patients.

Official Title

Use of FLIP Topography to Evaluate Esophageal Symptoms in Patients With Scleroderma

Eligibility Criteria

Ages Eligible for Study: 18 Years to 90 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

John Clarke, MD
Gastroenterologist, Motility specialist
Clinical Associate Professor, Medicine - Gastroenterology & Hepatology

Contact us to find out if this trial is right for you.

CONTACT

John O Clarke, MD
(650) 736-5555